FDA Approves First New Motion Sickness Drug in Over 40 Years: Vanda's Nereus Offers Hope for Travelers

Spread the Message

Read Time:3 Minute, 1 Second

The U.S. Food and Drug Administration (FDA) approved Vanda Pharmaceuticals’ Nereus (tradipitant) on December 30, 2025, for preventing vomiting induced by motion sickness. This marks the first novel pharmacologic treatment for the condition in more than four decades, potentially benefiting millions affected by travel-related nausea.

Key Clinical Evidence

Three pivotal trials supported the approval, including two Phase III real-world studies—Motion Syros and Motion Serifos—conducted on boats with participants prone to motion sickness. In these trials totaling 681 patients, tradipitant significantly reduced vomiting incidence: only 10.4% on the 170 mg dose and 18.3% on the 85 mg dose vomited, compared to 37.7% on placebo, achieving over 70% and 50% risk reductions respectively. A supportive trial further confirmed efficacy, with tradipitant preventing severe nausea and vomiting better than placebo (18.03% vs. 37.70%, p < 0.0001). Taken as an oral capsule before motion exposure, tradipitant targets neurokinin-1 (NK1) receptors in the brain linked to nausea signals.

Drug Mechanism and Development History

Tradipitant, licensed from Eli Lilly in 2012, blocks NK1 receptors to interrupt mismatched signals from the eyes, inner ear, and body sensors that trigger motion sickness. Vanda faced a partial clinical hold in 2018 over toxicity concerns but resolved it in December 2025 after FDA reclassified motion sickness as acute, not chronic. Vanda CEO Mihael H. Polymeropoulos stated, “This approval underscores the strong scientific evidence in the antiemetic effects of Nereus™… offering effective prevention without the limitations of existing options.” The company plans a U.S. launch in coming months, with analysts projecting peak sales over $100 million.

Expert Perspectives

Dr. Robert Barrie, a pharmaceutical analyst, noted the approval’s significance: “Nereus becomes the first pharmacological-based therapy to win the agency’s greenlight in this indication in over four decades.” Independent experts praise its profile. “Unlike scopolamine patches or antihistamines like Dramamine, which often cause drowsiness or dry mouth, tradipitant showed mild side effects like somnolence (12% at 170 mg) and headache (7-10%), making it suitable for short-term use,” said a reviewer of related NK1 studies. No new safety signals emerged across over 800 participants.

Motion Sickness Context

Motion sickness affects 25-30% of the global population, with higher rates in women (27.3% vs. 16.8% in men) and children (up to 43% in vehicles). It disrupts travel, military operations, and daily activities like boating or flying, occurring in about 0.13% of train rides but up to 4% in cars. Current options—scopolamine (Transderm Scop), meclizine (Bonine), and dimenhydrinate (Dramamine)—rely on older mechanisms with sedative effects that impair alertness. Tradipitant addresses this gap with modern neuropharmacology.

Public Health Implications

For travelers, sailors, pilots, and amusement park visitors, Nereus means proactive vomiting prevention without heavy sedation, enhancing safety and enjoyment. In military contexts, reduced susceptibility could boost operational readiness, as motion sickness hampers performance. Vanda explores tradipitant for gastroparesis and GLP-1 nausea (affecting 30-50% of users), potentially expanding access. Practical use: Take 85-170 mg orally before exposure; consult providers for interactions.

Limitations and Considerations

While effective, trials focused on vomiting prevention, not all symptoms like dizziness. Safety data show common mild effects—somnolence, fatigue, headache—but long-term use beyond acute events remains untested. Cost and availability details are pending, and it’s not for chronic conditions. Experts urge combining with non-drug strategies like horizon-gazing or ginger. Ongoing studies monitor broader applications.